387 related articles for article (PubMed ID: 26183926)
1. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
Donia M; Andersen R; Kjeldsen JW; Fagone P; Munir S; Nicoletti F; Andersen MH; Thor Straten P; Svane IM
Cancer Res; 2015 Sep; 75(18):3747-59. PubMed ID: 26183926
[TBL] [Abstract][Full Text] [Related]
2. HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes.
Le Dréan E; Gervois N; Diez E; Semana G; Dreno B; Jotereau F
Eur J Immunol; 1995 Oct; 25(10):2732-6. PubMed ID: 7589064
[TBL] [Abstract][Full Text] [Related]
3. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
4. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
Nishimura MI; Avichezer D; Custer MC; Lee CS; Chen C; Parkhurst MR; Diamond RA; Robbins PF; Schwartzentruber DJ; Rosenberg SA
Cancer Res; 1999 Dec; 59(24):6230-8. PubMed ID: 10626817
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
[TBL] [Abstract][Full Text] [Related]
6. A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma.
Somasundaram R; Swoboda R; Caputo L; Lee A; Jackson N; Marincola FM; Guerry D; Herlyn D
Int J Cancer; 2003 Apr; 104(3):362-8. PubMed ID: 12569560
[TBL] [Abstract][Full Text] [Related]
7. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
8. IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
Parrot T; Allard M; Oger R; Benlalam H; Raingeard de la Blétière D; Coutolleau A; Preisser L; Desfrançois J; Khammari A; Dréno B; Labarrière N; Delneste Y; Guardiola P; Gervois N
Eur J Immunol; 2016 Jul; 46(7):1770-82. PubMed ID: 27094152
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
11. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
[TBL] [Abstract][Full Text] [Related]
12. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes.
Markus NR; Rosenberg SA; Topalian SL
J Interferon Cytokine Res; 1995 Aug; 15(8):739-46. PubMed ID: 8528947
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
15. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
17. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
18. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
19. Classification of CD4+ T helper cell clones in human melanoma.
Goedegebuure PS; Lee KY; Matory YL; Peoples GE; Yoshino I; Eberlein TJ
Cell Immunol; 1994 Jun; 156(1):170-9. PubMed ID: 7911074
[TBL] [Abstract][Full Text] [Related]
20. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
